0001209191-23-014276.txt : 20230301
0001209191-23-014276.hdr.sgml : 20230301
20230301181709
ACCESSION NUMBER: 0001209191-23-014276
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230227
FILED AS OF DATE: 20230301
DATE AS OF CHANGE: 20230301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Davis Andrew
CENTRAL INDEX KEY: 0001932525
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34620
FILM NUMBER: 23695534
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET
STREET 2: SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001446847
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043404176
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-27
0
0001446847
IRONWOOD PHARMACEUTICALS INC
IRWD
0001932525
Davis Andrew
C/O IRONWOOD PHARMACEUTICALS, INC.
100 SUMMER STREET, SUITE 2300
BOSTON
MA
02110
0
1
0
0
SVP, Chief Business Officer
Class A Common Stock
2023-02-27
4
S
0
1751
11.41
D
153218
D
Class A Common Stock
2023-02-28
4
S
0
1822
11.31
D
151396
D
The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.29 to $11.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The reporting person acquired 756 shares of Class A Common Stock under the issuer's employee stock purchase plan on December 31, 2022.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Brian Tessler, Attorney-in-Fact
2023-03-01